THMO [NASD]
ThermoGenesis Holdings, Inc.
Index- P/E- EPS (ttm)-0.96 Insider Own13.48% Shs Outstand11.91M Perf Week-4.54%
Market Cap4.90M Forward P/E1.64 EPS next Y0.21 Insider Trans0.00% Shs Float11.06M Perf Month-40.42%
Income-11.40M PEG- EPS next Q0.02 Inst Own2.20% Short Float0.88% Perf Quarter-52.73%
Sales9.30M P/S0.53 EPS this Y63.00% Inst Trans-36.94% Short Ratio0.52 Perf Half Y-74.63%
Book/sh0.32 P/B1.08 EPS next Y90.90% ROA-51.80% Target Price- Perf Year-85.63%
Cash/sh0.51 P/C0.67 EPS next 5Y- ROE-161.20% 52W Range0.31 - 3.16 Perf YTD-65.84%
Dividend- P/FCF- EPS past 5Y50.60% ROI- 52W High-87.42% Beta2.98
Dividend %- Quick Ratio1.50 Sales past 5Y-8.50% Gross Margin37.60% 52W Low28.09% ATR0.05
Employees39 Current Ratio2.40 Sales Q/Q26.30% Oper. Margin-72.00% RSI (14)40.02 Volatility14.95% 11.82%
OptionableNo Debt/Eq2.63 EPS Q/Q38.00% Profit Margin- Rel Volume0.30 Prev Close0.34
ShortableYes LT Debt/Eq2.42 EarningsMay 19 AMC Payout- Avg Volume188.07K Price0.40
Recom- SMA20-8.45% SMA50-27.36% SMA200-67.98% Volume10,946 Change15.25%
May-23-18Initiated H.C. Wainwright Buy
Dec-22-15Downgrade Maxim Group Buy → Hold
Nov-17-15Reiterated Maxim Group Buy $7 → $1
Sep-21-15Upgrade H.C. Wainwright Neutral → Buy $2
May-15-15Downgrade H.C. Wainwright Buy → Neutral
Jun-26-14Initiated H.C. Wainwright Buy $5
Apr-24-14Initiated Maxim Group Buy $7
May-19-22 04:05PM  
May-18-22 08:30AM  
May-15-22 10:58AM  
May-09-22 05:25PM  
May-05-22 07:15PM  
Mar-28-22 04:05PM  
Mar-23-22 08:30AM  
Mar-14-22 09:35AM  
Jan-11-22 01:00PM  
Jan-10-22 08:30AM  
Dec-17-21 02:16PM  
Dec-06-21 12:50PM  
Nov-12-21 04:05PM  
Nov-05-21 08:30AM  
Nov-04-21 03:01PM  
Sep-14-21 08:30AM  
Sep-07-21 08:30AM  
Aug-12-21 06:15PM  
04:05PM  
Aug-06-21 03:00PM  
Aug-05-21 01:50PM  
Jun-08-21 07:29AM  
May-13-21 04:05PM  
02:30PM  
May-06-21 08:30AM  
Apr-30-21 04:55PM  
Mar-17-21 04:05PM  
02:30PM  
Mar-10-21 08:30AM  
Feb-17-21 08:30AM  
Feb-03-21 08:30AM  
Jan-07-21 08:30AM  
Dec-10-20 04:31AM  
Nov-12-20 04:05PM  
02:30PM  
Nov-05-20 08:30AM  
Oct-20-20 08:30AM  
Sep-11-20 03:34PM  
Sep-02-20 08:30AM  
Aug-31-20 08:30AM  
Aug-14-20 04:05PM  
Aug-13-20 08:30AM  
Aug-11-20 04:05PM  
Aug-05-20 08:30AM  
Jun-23-20 01:38PM  
Jun-16-20 08:30AM  
Jun-11-20 08:30AM  
Jun-08-20 01:07PM  
May-28-20 02:42PM  
May-18-20 08:57AM  
May-14-20 04:05PM  
May-07-20 08:30AM  
Apr-24-20 08:30AM  
Apr-16-20 08:45AM  
Apr-13-20 08:30AM  
Apr-03-20 08:30AM  
Apr-02-20 10:33AM  
Mar-31-20 08:30AM  
Mar-27-20 02:52PM  
Mar-25-20 08:57AM  
Mar-24-20 08:30AM  
Mar-18-20 08:30AM  
Feb-19-20 04:00PM  
Jan-03-20 08:30AM  
Jan-02-20 08:30AM  
Dec-10-19 08:30AM  
Dec-05-19 08:30AM  
Nov-26-19 08:30AM  
Nov-19-19 04:05PM  
Nov-14-19 03:44PM  
Nov-12-19 02:46PM  
Nov-06-19 08:30AM  
Oct-31-19 06:30AM  
Oct-24-19 08:30AM  
Oct-23-19 09:27AM  
12:47AM  
Oct-22-19 06:30AM  
Oct-14-19 08:30AM  
Oct-09-19 09:14AM  
Oct-02-19 08:30AM  
Sep-30-19 10:05AM  
Sep-25-19 10:25AM  
Sep-18-19 10:20AM  
Sep-09-19 12:17PM  
08:30AM  
Sep-03-19 08:30AM  
Aug-27-19 09:04AM  
Aug-26-19 05:47PM  
Aug-13-19 04:05PM  
Aug-06-19 08:30AM  
Jul-23-19 08:30AM  
Jul-05-19 10:25AM  
Jun-26-19 08:30AM  
Jun-25-19 08:30AM  
Jun-18-19 10:27AM  
08:30AM  
Jun-05-19 08:30AM  
Jun-04-19 12:00PM  
May-16-19 09:02AM  
May-14-19 04:05PM  
ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for chimeric antigen receptor (CAR-T) and other cell-based therapies. It markets a suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. The company manufactures and markets AXP II Automated Cell Separation System, an automated cell separation system for isolating stem and progenitor cells from umbilical cord blood; and BioArchive Automated Cryopreservation System, an automated, robotic, liquid nitrogen controlled-rate-freezing, and cryogenic storage system for cord blood samples and cell therapeutic products used in clinical applications. It offers PXP Point-of-Care System, an automated sterile system for the automated processing of autologous peripheral blood or bone marrow aspirate derived stem cells at the point-of-care, such as surgical centers or clinics; PXP-LAVARE System, an automated system designed to wash, re-suspend, and volume reduce cell suspensions; PXP-1000 System, an automated system for fast and reproducible separation of multiple cellular components from blood with minimal red blood cell contamination; and X-Series products, such as X-Lab for cell isolation, X-Wash System for cell washing and reformulation, X-Mini for small scale cell purification, and X-BACS System under development for large scale cell purification. It also provides CAR-TXpress Platform that addresses the critical unmet need for large scale cellular processing and chemistry, manufacturing, and controls needs. The company was formerly known as Cesca Therapeutics Inc. and changed its name to ThermoGenesis Holdings, Inc. in November 2019. ThermoGenesis Holdings, Inc. was incorporated in 1986 and is headquartered in Rancho Cordova, California.